Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FAZA PET Imaging in Breast Cancer
NCT00771381Phase 2Terminated
- Sponsor
- American Health Staffing Group
- Start
- Nov 2008
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluoroazomycin arabinoside F-18 in breast carcinoma, sponsored by American Health Staffing Group. Primary endpoint: Uptake of 18F-FAZA (RUS and T/B) and its correlation to tumour size, auxiliary nodal status, tumour grade, EP/PR, and HER-2 status, Ki-67, Androgen receptor status (AR), vimentin and basal keratins,… at 5 years. Started Nov 2008; status: terminated.
02
Drugs
Fluoroazomycin arabinoside F-18
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT00771381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771381.